Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioVie Inc.
  6. News
  7. Summary
    BIVI   US09074F2074

BIOVIE INC.

(BIVI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BIOVIE INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

10/14/2021 | 08:05am EST

Item 5.07. Submission of Matters to a Vote of Security Holders.

On October 13, 2021, BioVie Inc., a Nevada corporation (the "Company") held its 2021 Annual Meeting of stockholders (the "Annual Meeting"). The following matters were considered:




1. Election of Directors



Stockholders elected all of the Company's nominees for director for one-year
terms expiring on the next annual meeting of stockholders. The voting results
were as follows:



                                 For        Withhold     Broker Non-Vote
(1) TERREN S. PEIZER          20,445,440     391,779        1,865,518
(2) CUONG DO                  20,823,834      13,385        1,865,518
(3) JIM LANG                  20,821,158      16,061        1,865,518
(4) MICHAEL SHERMAN           20,823,833      13,386        1,865,518
(5) RICHARD J. BERMAN         20,302,945     534,274        1,865,518
(6) STEVE GORLIN              20,823,833      13,386        1,865,518

(7) ROBERT HARIRI, M.D. PHD 20,821,025 16,194 1,865,518 (8) SIGMUND ROGICH

            20,823,833      13,386        1,865,518




2. Approval and Ratification of Auditors

Stockholders approved and ratified the appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the 2022 fiscal year. The voting results were as follows:



   For       Against   Abstain   Broker Non-Vote
22,674,262   26,010     2,465          -0-



3. Advisory Say-on-Pay Resolution

Stockholders approved the following resolution "RESOLVED" that the stockholders approve the compensation of the Company's named executive officers as disclosed in the compensation tables and the related disclosure contained in the proxy statement. The voting results were as follows:




   For       Against   Abstain   Broker Non-Vote
20,780,782   27,943    28,494       1,865,518




4. Advisory Resolution on Frequency of Say-on-Pay Resolution

Stockholders approved the following resolution "RESOLVED" that the stockholders wish the Company to include an advisory vote on the compensation of the Company's named executive officers pursuant to Section 14A of the Securities Exchange Act of 1934 every (i) year, (ii) two years, or (iii) three years (select one). The voting results were as follows:

Three Years Two Years One Year Abstain Broker Non-Vote 20,200,510 5,100 596,674 34,935 1,865,518

In light of the foregoing vote regarding Proposal Four, the Company has decided to include an advisory stockholder vote on the compensation of executives in its proxy materials every three years.

                                      -2-

© Edgar Online, source Glimpses

All news about BIOVIE INC.
12/01BIOVIE : Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fun..
PU
12/01BIOVIE INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial O..
AQ
12/01BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fu..
AQ
11/30B. Riley Lowers BioVie's PT to $27 from $50 to Reflect Continued Expansion in Research,..
MT
11/10BIOVIE INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
11/10BioVie Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021
CI
11/04BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis ..
AQ
11/01BioVie Announces the Appointment of a New Chief Medical Officer
AQ
11/01BioVie Inc. Announces Appointment of Joseph M. Palumbo as Chief Medical Officer
CI
10/26BioVie Secures FDA Approval for Phase 2 Trial of Potential Parkinson's Disease Treatmen..
MT
More news
Analyst Recommendations on BIOVIE INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -82,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,83x
Yield 2022 -
Capitalization 130 M 130 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 6
Free-Float 20,3%
Chart BIOVIE INC.
Duration : Period :
BioVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 5,22 $
Average target price 27,00 $
Spread / Average Target 417%
EPS Revisions
Managers and Directors
Cuong Viet Do President, Chief Executive Officer & Director
Joanne Wendy Kim Chief Financial Officer & Secretary
Terren S. Peizer Chairman
Joseph M. Palumbo Chief Medical Officer
James D. Lang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOVIE INC.-69.17%133
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.21.78%65 758
VERTEX PHARMACEUTICALS-13.76%51 819